Autoantibody neutralization

"Autoantibody neutralization" is **not** the name of a specific molecule or receptor. Instead, it refers to the process by which autoantibodies—immune system antibodies that mistakenly recognize and bind self-molecules—neutralize the biological function of their targets. This phenomenon is observed in various autoimmune conditions where autoantibodies block or inhibit endogenous proteins such as cytokines, hormones, or cell-surface receptors. For example, **neutralizing autoantibodies against type I interferons** can block these critical antiviral cytokines from binding their receptors on cells. This impairs antiviral immunity and increases susceptibility to severe viral infections[2][5]. The mechanism involves high-affinity binding by the autoantibody that prevents interaction between the endogenous molecule and its physiological receptor[2][5]. Similar mechanisms are seen with other targets like acetylcholine receptor in myasthenia gravis[1]. Therapeutic approaches do not directly "target" this process but may aim to remove pathogenic autoantibodies from circulation or restore function using engineered decoy molecules that absorb these antibodies without triggering downstream effects[2]. Because "autoantibody neutralization" describes an immunopathological mechanism rather than a discrete protein/gene/receptor/enzyme entity, it should **not be considered a canonical therapeutic target**. It is more accurately described as an immunological event relevant across multiple diseases. If you are seeking structured information about specific molecules involved in this process—such as "Type I interferon," "Acetylcholine receptor," etc.—those would be appropriate canonical targets with defined names and properties.